Bjork T - Search Results

1

Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.

LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, Baselga J. LoRusso PM, et al. Among authors: bjork t. Clin Cancer Res. 2003 Jun;9(6):2040-8. Clin Cancer Res. 2003. PMID: 12796366

2

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J. Baselga J, et al. Among authors: bjork t. J Clin Oncol. 2002 Nov 1;20(21):4292-302. doi: 10.1200/JCO.2002.03.100. J Clin Oncol. 2002. PMID: 12409327 Clinical Trial.

3

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.

Ulmert D, Serio AM, O'Brien MF, Becker C, Eastham JA, Scardino PT, Björk T, Berglund G, Vickers AJ, Lilja H. Ulmert D, et al. Among authors: bjork t. J Clin Oncol. 2008 Feb 20;26(6):835-41. doi: 10.1200/JCO.2007.13.1490. J Clin Oncol. 2008. PMID: 18281654

4

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.

Lilja H, Ulmert D, Björk T, Becker C, Serio AM, Nilsson JA, Abrahamsson PA, Vickers AJ, Berglund G. Lilja H, et al. Among authors: bjork t. J Clin Oncol. 2007 Feb 1;25(4):431-6. doi: 10.1200/JCO.2006.06.9351. J Clin Oncol. 2007. PMID: 17264339

5

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.

Vickers AJ, Ulmert D, Serio AM, Björk T, Scardino PT, Eastham JA, Berglund G, Lilja H. Vickers AJ, et al. Among authors: bjork t. Int J Cancer. 2007 Nov 15;121(10):2212-7. doi: 10.1002/ijc.22956. Int J Cancer. 2007. PMID: 17657743

6

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.

Ulmert D, Cronin AM, Björk T, O'Brien MF, Scardino PT, Eastham JA, Becker C, Berglund G, Vickers AJ, Lilja H. Ulmert D, et al. Among authors: bjork t. BMC Med. 2008 Feb 15;6:6. doi: 10.1186/1741-7015-6-6. BMC Med. 2008. PMID: 18279502 Free PMC article.

7

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

Vickers AJ, Cronin AM, Björk T, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Ulmert D, Lilja H. Vickers AJ, et al. Among authors: bjork t. BMJ. 2010 Sep 14;341:c4521. doi: 10.1136/bmj.c4521. BMJ. 2010. PMID: 20843935 Free PMC article.

8

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.

Vickers AJ, Ulmert D, Sjoberg DD, Bennette CJ, Björk T, Gerdtsson A, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Lilja H. Vickers AJ, et al. Among authors: bjork t. BMJ. 2013 Apr 15;346:f2023. doi: 10.1136/bmj.f2023. BMJ. 2013. PMID: 23596126 Free PMC article.

9

Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C.

Ulmert D, Becker C, Nilsson JA, Piironen T, Björk T, Hugosson J, Berglund G, Lilja H. Ulmert D, et al. Among authors: bjork t. Clin Chem. 2006 Feb;52(2):235-9. doi: 10.1373/clinchem.2005.050641. Epub 2005 Dec 29. Clin Chem. 2006. PMID: 16384894

10

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.

Christensson A, Bruun L, Björk T, Cronin AM, Vickers AJ, Savage CJ, Lilja H. Christensson A, et al. Among authors: bjork t. BJU Int. 2011 Jun;107(11):1769-74. doi: 10.1111/j.1464-410X.2010.09761.x. Epub 2010 Oct 18. BJU Int. 2011. PMID: 20955263 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

48 results

Search Page